SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES AND CONSOLIDATED NET LOSS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Research and development expenses	$ 11,639,411	$ 11,287,691
General and administrative expenses	7,493,035	9,742,739
Total operating expenses	19,132,446	21,030,430
Loss from operations	(19,132,446)	(21,030,430)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Research and development expenses	11,639,000	11,288,000
Change Increase (Decrease), Research and development expenses	$ 351,000
Change Increase (Decrease), Research and development expenses, percentage	3.10%
General and administrative expenses	$ 7,493,000	9,742,000
Change Increase (Decrease), General and administrative expenses	$ (2,249,000)
Change Increase (Decrease), General and administrative expenses, percentage	(23.10%)
Total operating expenses	$ 19,132,000	21,030,000
Change Increase (Decrease), Operating expenses	$ (1,898,000)
Change Increase (Decrease), Operating expenses, percentage	(9.00%)
Loss from operations	$ (19,132,000)	(21,030,000)
Change Increase (Decrease), Loss from operations	$ (1,898,000)
Change Increase (Decrease), Loss from operations, percentage	(9.00%)
Operating Segments [Member] | Clinical Research [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 5,240,000	2,990,000
Change Increase (Decrease), Subtotal	$ 2,250,000
Change Increase (Decrease), Subtotal, percentage	75.30%
Operating Segments [Member] | Clinical Research [Member] | Ovation [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 1,386,000	1,197,000
Change Increase (Decrease), Subtotal	$ 189,000
Change Increase (Decrease), Subtotal, percentage	15.80%
Operating Segments [Member] | Clinical Research [Member] | Vaccine [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 1,420,000
Change Increase (Decrease), Subtotal	$ 1,420,000
Change Increase (Decrease), Subtotal, percentage	100.00%
Operating Segments [Member] | Clinical Research [Member] | Other Clinical And Regulatory [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 2,434,000	1,793,000
Change Increase (Decrease), Subtotal	$ 641,000
Change Increase (Decrease), Subtotal, percentage	35.80%
Operating Segments [Member] | Non-Clinical R&D and CMC [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 6,399,000	8,298,000
Change Increase (Decrease), Subtotal	$ (1,899,000)
Change Increase (Decrease), Subtotal, percentage	(22.90%)
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Ovation [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 1,819,000	1,504,000
Change Increase (Decrease), Subtotal	$ 315,000
Change Increase (Decrease), Subtotal, percentage	20.90%
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | PlaCCine Vaccine [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 2,554,000	4,511,000
Change Increase (Decrease), Subtotal	$ (1,957,000)
Change Increase (Decrease), Subtotal, percentage	(43.40%)
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Manufacturing (CMC) [Member]
Segment Reporting Information [Line Items]
Subtotal	$ 2,026,000	$ 2,283,000
Change Increase (Decrease), Subtotal	$ (257,000)
Change Increase (Decrease), Subtotal, percentage	(11.30%)